The accumulation and aggregation of amyloid beta (Aβ)—a peptide fragment derived from the proteolytic processing of amyloid precursor protein (APP)—is a central pathological feature of Alzheimer’s disease (AD) and a current target for disease-modifying therapies. This evidence concerns the gene APP and Alzheimer disease.